4-Fluorophenibut

4-Fluorophenibut (developmental code name CGP-11130; also known as β-(4-fluorophenyl)-γ-aminobutyric acid or β-(4-fluorophenyl)-GABA) is a GABAB receptor agonist which was never marketed.[1] It is selective for the GABAB receptor over the GABAA receptor (IC50 = 1.70 μM and > 100 μM, respectively).[1] The drug is a GABA analogue and is closely related to baclofen (β-(4-chlorophenyl)-GABA), tolibut (β-(4-methylphenyl)-GABA), and phenibut (β-phenyl-GABA).[1] It is less potent as a GABAB receptor agonist than baclofen but more potent than phenibut.[1]

4-Fluorophenibut
Clinical data
Other namesCGP-11130; β-(4-Fluorophenyl)-γ-aminobutyric acid; β-(4-Fluorophenyl)-GABA; Baflofen; Fluorophenibut; F-Phenibut; Fluoribut
Routes of
administration
By mouth
Identifiers
CAS Number
PubChem CID
ChemSpider
Chemical and physical data
FormulaC10H12FNO2
Molar mass197.209 g·mol−1
3D model (JSmol)

The substance is sometimes referred to as 4F-phenibut or F-phenibut and colloquially as fluorobut.

References

  1. Bowery NG, Hill DR, Hudson AL (1983). "Characteristics of GABAB receptor binding sites on rat whole brain synaptic membranes". Br. J. Pharmacol. 78 (1): 191–206. doi:10.1111/j.1476-5381.1983.tb09380.x. PMC 2044790. PMID 6297646.


This article is issued from Wikipedia. The text is licensed under Creative Commons - Attribution - Sharealike. Additional terms may apply for the media files.